259 related articles for article (PubMed ID: 3446554)
21. Proglucagon processing in porcine and human pancreas.
Holst JJ; Bersani M; Johnsen AH; Kofod H; Hartmann B; Orskov C
J Biol Chem; 1994 Jul; 269(29):18827-33. PubMed ID: 8034635
[TBL] [Abstract][Full Text] [Related]
22. Glicentin and gastric inhibitory polypeptide immunoreactivity in endocrine cells of the gut and pancreas.
Larsson LI; Moody AJ
J Histochem Cytochem; 1980 Sep; 28(9):925-33. PubMed ID: 6997368
[TBL] [Abstract][Full Text] [Related]
23. Glicentin is present in the pig pancreas.
Sheikh SP; Baldissera FG; Karlsen FO; Holst JJ
FEBS Lett; 1985 Jan; 179(1):1-6. PubMed ID: 3965295
[TBL] [Abstract][Full Text] [Related]
24. Purification and sequence of rat oxyntomodulin.
Collie NL; Walsh JH; Wong HC; Shively JE; Davis MT; Lee TD; Reeve JR
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9362-6. PubMed ID: 7937770
[TBL] [Abstract][Full Text] [Related]
25. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut.
Böttcher G; Sjölund K; Ekblad E; Håkanson R; Schwartz TW; Sundler F
Regul Pept; 1984 Jul; 8(4):261-6. PubMed ID: 6548568
[TBL] [Abstract][Full Text] [Related]
26. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.
Schjoldager BT; Mortensen PE; Christiansen J; Orskov C; Holst JJ
Dig Dis Sci; 1989 May; 34(5):703-8. PubMed ID: 2714145
[TBL] [Abstract][Full Text] [Related]
27. Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas.
Ali-Rachedi A; Varndell IM; Adrian TE; Gapp DA; Van Noorden S; Bloom SR; Polak JM
Histochemistry; 1984; 80(5):487-91. PubMed ID: 6384152
[TBL] [Abstract][Full Text] [Related]
28. Presence of glucagon-(1-21)-Like immunoreactive substance in the dog small intestinal mucosa.
Itoh H; Namba M; Watanabe N; Ohara T; Matsuyama T; Komatsu R; Shinomura Y; Kono N; Tarui S
Biochem Biophys Res Commun; 1989 Dec; 165(3):1010-7. PubMed ID: 2610678
[TBL] [Abstract][Full Text] [Related]
29. Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin--current status.
Holst JJ
Gastroenterology; 1983 Jun; 84(6):1602-13. PubMed ID: 6188645
[TBL] [Abstract][Full Text] [Related]
30. Decrease in plasma GLP-1 immunoreactivity in starved rats.
Takahashi J; Noma Y; Yoshimoto S; Fujita C; Shima K
Diabetes Res Clin Pract; 1992 Mar; 15(3):205-12. PubMed ID: 1374310
[TBL] [Abstract][Full Text] [Related]
31. Gastric inhibitory peptide-like immunoreactivity in glucagon and glicentin cells: properties and origin. An immunocytochemical study using several antisera.
Sjölund K; Ekelund M; Håkanson R; Moody AJ; Sundler F
J Histochem Cytochem; 1983 Jun; 31(6):811-7. PubMed ID: 6188783
[TBL] [Abstract][Full Text] [Related]
32. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas.
Mojsov S; Kopczynski MG; Habener JF
J Biol Chem; 1990 May; 265(14):8001-8. PubMed ID: 1692320
[TBL] [Abstract][Full Text] [Related]
33. Alterations in proglucagon processing and inhibition of proglucagon gene expression in transgenic mice which contain a chimeric proglucagon-SV40 T antigen gene.
Brubaker PL; Lee YC; Drucker DJ
J Biol Chem; 1992 Oct; 267(29):20728-33. PubMed ID: 1328210
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide-1, a new hormone of the entero-insular axis.
Orskov C
Diabetologia; 1992 Aug; 35(8):701-11. PubMed ID: 1324859
[TBL] [Abstract][Full Text] [Related]
35. Distribution and molecular forms of glucagon-like peptide in the dog.
Suda K; Takahashi H; Fukase N; Manaka H; Tominaga M; Sasaki H
Life Sci; 1989; 45(19):1793-8. PubMed ID: 2593768
[TBL] [Abstract][Full Text] [Related]
36. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
Orskov C; Jeppesen J; Madsbad S; Holst JJ
J Clin Invest; 1991 Feb; 87(2):415-23. PubMed ID: 1991827
[TBL] [Abstract][Full Text] [Related]
37. Primary structures of three fragments of proglucagon from the pancreatic islets of the daddy Sculpin (Cottus scorpius).
Conlon JM; Falkmer S; Thim L
Eur J Biochem; 1987 Apr; 164(1):117-22. PubMed ID: 3549298
[TBL] [Abstract][Full Text] [Related]
38. The Enigmatic N-Terminal Domain of Proglucagon; A Historical Perspective.
Conlon JM
Front Endocrinol (Lausanne); 2021; 12():683089. PubMed ID: 34177808
[TBL] [Abstract][Full Text] [Related]
39. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.
Jeppesen PB; Hartmann B; Thulesen J; Hansen BS; Holst JJ; Poulsen SS; Mortensen PB
Gut; 2000 Sep; 47(3):370-6. PubMed ID: 10940274
[TBL] [Abstract][Full Text] [Related]
40. Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas.
Philippe J; Mojsov S; Drucker DJ; Habener JF
Endocrinology; 1986 Dec; 119(6):2833-9. PubMed ID: 3536450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
